Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Neuromuscular diseases rehabilitation in the era of gene therapy

This is a preview of subscription content, log in to check access.

References

  1. 1.

    High KA, Roncarolo MG (2019) Gene therapy. N Engl J Med 381(5):455–464. https://doi.org/10.1056/NEJMra1706910

  2. 2.

    Vita G, Vita GL, Musumeci O, Rodolico C, Messina S (2019) Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 40(4):671–681. https://doi.org/10.1007/s10072-019-03764-z

  3. 3.

    Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S (2018) Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28(2):103–115

  4. 4.

    Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S (2018) Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 28(3):197–207

  5. 5.

    Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet Neurology 17(3):251–267. https://doi.org/10.1016/s1474-4422(18)30024-3

  6. 6.

    Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. The Lancet Neurology 17(4):347–361. https://doi.org/10.1016/s1474-4422(18)30025-5

  7. 7.

    Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR, Ward LM (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. The Lancet Neurology 17(5):445–455. https://doi.org/10.1016/s1474-4422(18)30026-7

  8. 8.

    Hoy SM (2019) Onasemnogene abeparvovec: first global approval. Drugs 79(11):1255–1262. https://doi.org/10.1007/s40265-019-01162-5

  9. 9.

    Kuruvilla J, Sasmita AO, Ling APK (2018) Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 39(11):1827–1835. https://doi.org/10.1007/s10072-018-3521-0

  10. 10.

    Mendell JR, Rodino-Klapac LR (2016) Duchenne muscular dystrophy: CRISPR/Cas9 treatment. Cell Res 26(5):513–514. https://doi.org/10.1038/cr.2016.28

  11. 11.

    Hoy SM (2017) Nusinersen: first global approval. Drugs 77(4):473–479. https://doi.org/10.1007/s40265-017-0711-7

  12. 12.

    Trabacca A, Lucarelli E, Pacifico R, Vespino T, Di Liddo A, Losito L (2020) The ICF-CY as a framework for the management of spinal muscular atrophy in the era of gene therapy: a proof-of-concept study. European journal of physical and rehabilitation medicine. doi:https://doi.org/10.23736/s1973-9087.20.05968-7

  13. 13.

    Case LE, Apkon SD, Eagle M, Gulyas A, Juel L, Matthews D, Newton RA, Posselt HF (2018) Rehabilitation management of the patient with Duchenne muscular dystrophy. Pediatrics 142(Suppl 2):S17–s33. https://doi.org/10.1542/peds.2018-0333D

  14. 14.

    Quadrado VH, Silva TDD, Favero FM, Tonks J, Massetti T, Monteiro CBM (2019) Motor learning from virtual reality to natural environments in individuals with Duchenne muscular dystrophy. Disabil Rehabil Assist Technol 14(1):12–20. https://doi.org/10.1080/17483107.2017.1389998

  15. 15.

    Organization WH (2001) International classification of functioning, disability and health: ICF. World Health Organization, Geneva

  16. 16.

    Trabacca A, Russo L (2019) Children’s rare disease rehabilitation: from multidisciplinarity to the transdisciplinarity approach. Eur J Phys Rehabil Med 55(1):136–137. https://doi.org/10.23736/s1973-9087.17.04900-0

Download references

Author information

Correspondence to Antonio Trabacca.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Trabacca, A. Neuromuscular diseases rehabilitation in the era of gene therapy. Neurol Sci (2020). https://doi.org/10.1007/s10072-020-04280-1

Download citation